Table VIII.
Results of custom prostheses reconstruction and modular endoprosthesis reconstruction
| Custom prostheses reconstruction | |
| Studies, n | 5 |
| Reconstructions, n | 182 |
| Metastatic disease, n (%) | 26 (14) |
| Primary malignancy, n (%) | 156 (86) |
| Mean age in yrs, n (range) | 42 (10 to 81) |
| Male patients, n (%) | 88 (48) |
| Mean follow-up in yrs, n (range) | 4.4 (0.2 to 33.5) |
| MSTS score, % | 63 |
| Patient mortality, n (%) | |
| AWD | 75 (41) |
| DOD | 63 (35) |
| NED | 31 (19) |
| Implant survivorship from all-cause revision at final follow-up, % | 61 |
| Complications, n (%) | |
| Infection | 41 (23) |
| Local recurrence | 40 (22) |
| Dislocation | 31 (17) |
| Thrombotic complication | 11 (6) |
| Wound healing | 10 (5) |
| Nerve palsy | 6 (3) |
| Aseptic loosening | 2 (1) |
| Modular endoprosthesis reconstruction | |
| Studies, n | 5 |
| Reconstructions, n | 143 |
| Metastatic disease, n (%) | 31 (22) |
| Primary malignancy, n (%) | 112 (78) |
| Mean age in yrs, n (range) | 47 (12 to 81) |
| Male patients, n (%) | 84 (59) |
| Mean follow-up in yrs, n (range) | 5 (0.8 to 23.8) |
| MSTS score, % | 64 |
| Patient mortality, n (%) | |
| AWD | 50 (35) |
| DOD | 28 (20) |
| NED | 31 (22) |
| Implant survivorship from all-cause revision at final follow-up, % | 69 |
| Complications, n (%) | |
| Infection | 34 (24) |
| Dislocation | 18 (13) |
| Recurrence | 16 (11) |
| Aseptic loosening | 6 (4) |
| Wound healing | 3 (2) |
MSTS, Musculoskeletal Tumor Society; AWD, alive with disease; DOD, dead of disease; NED, no evidence of disease